THE LONGEVITY FOUNDATION premature agingthelongevityfoundation.org/wp-content/uploads/2017/02/...the...
2
THE LONGEVITY FOUNDATION “Collaborative biomedical research into cancer and degenerative diseases associated with auto-immunity, inflammation and premature aging” www.thelongevityfoundation.org [email protected] 1992-2017 Great Progress at Texas A&M As you may recall, The Longevity Foundaon has helped sup- port research by Ashok Shey, Ph.D., at Texas A&M, starng about three years ago. Paul Wong, Ph.D., our longme friend and lead researcher who recently rered from M.D. Ander- son, connues to work as a consultant to Dr. Shey. Dr. Shey has just completed the second phase of experi- ments using Bach Pharma’s non-toxic drug, GVT, in a pre- clinical model using mulple chemicals similar to those known to have caused Gulf War Illness (GWI). That illness has been reported in as many as one-third of the 700,000 service men and women who saw acon in that war. Their symptoms range from fague and weakness to depression, memory loss, and cognion difficules. The results of Dr. Shey’s study are astounding. This second phase of his study has further confirmed and broad- ened the indicaons of his first phase: GVT has a stascally significant impact in negang GWI symptoms, espe- cially at higher doses. His results show great improvements in behavioral tests of mood, memory, and cognion. Just as importantly, he also found scienfic evidence at the cellular level that corresponds with the behavioral improvements. The greatest implicaon for all of us is that GVT is now proven to smulate the hippocampus of the brain to resume regenerang neurons, a process which ceases with exposure to toxins, stress, and aging. New Work on Lou Gehrig’s Disease The Longevity Foundaon has just made a meaningful investment in new and ex- cing research into ALS, or Lou Gehrig’s disease, with Robert Brown, M.D., Ph.D., chair of the Department of Neurology at the University of Massachuses Medical School. Dr. Brown is one of the world’s leading experts in neuro-degenerave dis- eases and one of his chief collaborators at “UMass” is a Nobel Prize winner. Dr. Brown’s newest research project involves tesng the efficacy of GVT in replac- ing SOD1, which is one of the body’s most important molecules for prevenng oxi- dave damage, parcularly as it might be seen in prevenng ALS. The lack of SOD1 producon is present in over 90 percent of all ALS cases. The Longevity Foundaon’s funding is supporng the all-important pre-clinical tests that are necessary to provide the data to jusfy clinical trials. The pre-clinical tests are on a “fast track”, with results expected no later than mid-year. Once those results are in, funding is available for clinical trials, assuming that the prelim- inary tests confirm the expected outcomes. Ashok Shetty, Ph.D. Paul Wong, Ph.D. Robert Brown, M.D., Ph.D.
Transcript of THE LONGEVITY FOUNDATION premature agingthelongevityfoundation.org/wp-content/uploads/2017/02/...the...
THE
LONGEVITY
FOUNDATION
“Collaborative biomedical research into
cancer and degenerative diseases associated with auto-immunity, inflammation and
premature aging”
www.thelongevityfoundation.org [email protected]
1992-2017
Great Progress at Texas A&M
As you may recall, The Longevity Foundation has helped sup-port research by Ashok Shetty, Ph.D., at Texas A&M, starting about three years ago. Paul Wong, Ph.D., our longtime friend and lead researcher who recently retired from M.D. Ander-son, continues to work as a consultant to Dr. Shetty.
Dr. Shetty has just completed the second phase of experi-ments using Bach Pharma’s non-toxic drug, GVT, in a pre-clinical model using multiple chemicals similar to those known to have caused Gulf War Illness (GWI). That illness has been reported in as many as one-third of the 700,000 service men and women who saw action in that war. Their symptoms
range from fatigue and weakness to depression, memory loss, and cognition difficulties.
The results of Dr. Shetty’s study are astounding. This second phase of his study has further confirmed and broad-ened the indications of his first phase: GVT has a statistically significant impact in negating GWI symptoms, espe-cially at higher doses. His results show great improvements in behavioral tests of mood, memory, and cognition. Just as importantly, he also found scientific evidence at the cellular level that corresponds with the behavioral improvements. The greatest implication for all of us is that GVT is now proven to stimulate the hippocampus of the brain to resume regenerating neurons, a process which ceases with exposure to toxins, stress, and aging.
New Work on Lou Gehrig’s Disease
The Longevity Foundation has just made a meaningful investment in new and ex-citing research into ALS, or Lou Gehrig’s disease, with Robert Brown, M.D., Ph.D., chair of the Department of Neurology at the University of Massachusetts Medical School. Dr. Brown is one of the world’s leading experts in neuro-degenerative dis-eases and one of his chief collaborators at “UMass” is a Nobel Prize winner.
Dr. Brown’s newest research project involves testing the efficacy of GVT in replac-ing SOD1, which is one of the body’s most important molecules for preventing oxi-dative damage, particularly as it might be seen in preventing ALS. The lack of SOD1 production is present in over 90 percent of all ALS cases.
The Longevity Foundation’s funding is supporting the all-important pre-clinical tests that are necessary to provide the data to justify clinical trials. The pre-clinical tests are on a “fast track”, with results expected no later than mid-year. Once those results are in, funding is available for clinical trials, assuming that the prelim-inary tests confirm the expected outcomes.
Ashok Shetty, Ph.D. Paul Wong, Ph.D.
Robert Brown, M.D., Ph.D.
.
TO ORDER, GO TO:
www.thelongevityfoundation.org
Give your special Valentine{s) a gift especially created for The Longevity
Foundation by internationally-renowned artist Bill Worrell . These inscribed , limited-edition, sterling silver heart pendants convey an al-most tangible message of love and
hope and are sure to be treasured by the recipient(s).
Best Valentine’s gift ever!
THANK YOU FOR YOUR HELP! It is hard to imagine that in 2017, The Longevity Foundation is celebrating its 25th year of existence. Thanks to your gener-ous donations, we have been able to help fund cost-effective, results-oriented research that will bring treatments and cures for degenerative diseases in the fastest manner possible. We and our researchers greatly appreciate your support!
In Memoriam Shirley Howard
1928-2016
We give thanks for the life of Shirley Howard, who worked tirelessly for many years as the volunteer administrator of the A-T Project and then The Longevity Foundation. Shirley may have left us on this Earth, but her inspiration and goodness will live on forever.
George Stoica, Ph.D., at Texas A&M University, has collaborated for many years with Paul Wong, Ph.D., on unlocking the mysteries of neuronal degenera-tion. Dr. Stoica has received support from the Mi-chael J. Fox Foundation in developing a pre-clinical model for Parkinson’s disease and we are hopeful that funding will become available to test GVT with that model. Paul Wong, Ph.D. George Stoica, Ph.D.
Parkinson’s Discoveries
Handcrafted, sterling silver pendant Bill Worrell, artist, painter, sculptor, writer, jewelry maker, singer-songwriter
